Physician profile
Laura E Bauman
NPI 1255697850
$7,615.27
in general payments reported to CMS, 2019-2025
9 companies · $36.39 in 2025
The $36.39 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $2.39 · 2021: $93.19 · 2022: $1.02 · 2023: $139 · 2024: $7,219 · 2025: $36.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,033 · Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,032.62 |
| Food and Beverage | $361.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $7,194.64 | 2024 | Bylvay |
| Abbvie INC. | $216.23 | 2019-2021 | |
| Gilead Sciences, INC. | $101.31 | 2023 | |
| Qol Medical, LLC | $36.39 | 2025 | Sucraid |
| Alcresta Therapeutics, INC. | $24.24 | 2024 | Relizorb |
| Regeneron Healthcare Solutions, INC. | $23.46 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $14.57 | 2023 | Smoflipid |
| Travere Therapeutics, INC. | $4.43 | 2020-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bauman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.